You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Danaher expects shareholders will see returns from the acquisition in the fifth year, as post-acquisition cost savings and revenues kick in.
Trichomonas is a nonviral sexually transmitted disease caused by infection with the protozoan parasite Trichomonas vaginalis.
Danaher said that it expects the acquisition to be accretive to earnings in the fifth full year post acquisition.
Danaher Q2 net earnings fell 5 percent to $656.7 million, or $.94 per diluted share, from $695.7 million, or $.97 per diluted share, a year ago.